127 related articles for article (PubMed ID: 37742997)
21. Rifampin- and Silymarin-Mediated Pharmacokinetic Interactions of Exogenous and Endogenous Substrates in a Transgenic OATP1B Mouse Model.
Bechtold BJ; Lynch KD; Oyanna VO; Call MR; Graf TN; Oberlies NH; Clarke JD
Mol Pharm; 2024 May; 21(5):2284-2297. PubMed ID: 38529622
[TBL] [Abstract][Full Text] [Related]
22. Cluster Gauss-Newton method analyses of PBPK model parameter combinations of coproporphyrin-I based on OATP1B-mediated rifampicin interaction studies.
Yoshikado T; Aoki Y; Mochizuki T; Rodrigues AD; Chiba K; Kusuhara H; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1341-1357. PubMed ID: 35945914
[TBL] [Abstract][Full Text] [Related]
23. Repression of Organic Anion Transporting Polypeptide (OATP) 1B Expression and Increase of Plasma Coproporphyrin Level as Evidence for OATP1B Downregulation in Cynomolgus Monkeys Treated with Chenodeoxycholic Acid.
Zhang Y; Chen SJ; Chen C; Chen XQ; Chatterjee S; Shuster DJ; Dexter H; Armstrong L; Joshi EM; Yang Z; Shen H
Drug Metab Dispos; 2022 Aug; 50(8):1077-1086. PubMed ID: 35636769
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the Selectivity of Several Organic Anion Transporting Polypeptide 1B Biomarkers Using Relative Activity Factor Method.
Chan GH; Houle R; Zhang J; Katwaru R; Li Y; Chu X
Drug Metab Dispos; 2023 Sep; 51(9):1089-1104. PubMed ID: 37137718
[TBL] [Abstract][Full Text] [Related]
25. PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3.
Yoshikado T; Toshimoto K; Maeda K; Kusuhara H; Kimoto E; Rodrigues AD; Chiba K; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2018 Nov; 7(11):739-747. PubMed ID: 30175555
[TBL] [Abstract][Full Text] [Related]
26. Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI.
Jones NS; Yoshida K; Salphati L; Kenny JR; Durk MR; Chinn LW
Clin Pharmacol Ther; 2020 Jan; 107(1):269-277. PubMed ID: 31376152
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the Drug-Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults.
Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuzaki T; Matsuo Y; Kubota R
Clin Drug Investig; 2023 May; 43(5):335-346. PubMed ID: 37171749
[TBL] [Abstract][Full Text] [Related]
28. Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs.
Mochizuki T; Aoki Y; Yoshikado T; Yoshida K; Lai Y; Hirabayashi H; Yamaura Y; Rockich K; Taskar K; Takashima T; Chu X; Zamek-Gliszczynski MJ; Mao J; Maeda K; Furihata K; Sugiyama Y; Kusuhara H
Clin Transl Sci; 2022 Jun; 15(6):1519-1531. PubMed ID: 35421902
[TBL] [Abstract][Full Text] [Related]
29. Development of an LC-MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions.
Njumbe Ediage E; Dillen L; Vroman A; Diels L; Kunze A; Snoeys J; Verhaeghe T
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1073():80-89. PubMed ID: 29241088
[TBL] [Abstract][Full Text] [Related]
30. Alteration in the Plasma Concentrations of Endogenous Organic Anion-Transporting Polypeptide 1B Biomarkers in Patients with Non-Small Cell Lung Cancer Treated with Paclitaxel.
Mori D; Ishida H; Mizuno T; Kusumoto S; Kondo Y; Izumi S; Nakata G; Nozaki Y; Maeda K; Sasaki Y; Fujita KI; Kusuhara H
Drug Metab Dispos; 2020 May; 48(5):387-394. PubMed ID: 32114508
[TBL] [Abstract][Full Text] [Related]
31. A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.
Mukae H; Yotsuyanagi H; Ohmagari N; Doi Y; Imamura T; Sonoyama T; Fukuhara T; Ichihashi G; Sanaki T; Baba K; Takeda Y; Tsuge Y; Uehara T
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0069722. PubMed ID: 36098519
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model.
Fukao K; Nobori H; Kuroda T; Baba K; Matsumoto K; Tanaka Y; Tachibana Y; Kato T; Shishido T
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896829
[TBL] [Abstract][Full Text] [Related]
33. Effect of a Ketohexokinase Inhibitor (PF-06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe Drug.
Tess DA; Kimoto E; King-Ahmad A; Vourvahis M; Rodrigues AD; Bergman A; Qui R; Somayaji V; Weng Y; Fonseca KR; Litchfield J; Varma MVS
Clin Pharmacol Ther; 2022 Sep; 112(3):605-614. PubMed ID: 35355249
[TBL] [Abstract][Full Text] [Related]
34. Computational Estimation of Residues Involving Resistance to the SARS-CoV-2 Main Protease Inhibitor Ensitrelvir Based on Virtual Alanine Scan of the Active Site.
Mizuno A; Nakayoshi T; Kato K; Kurimoto E; Oda A
Biol Pharm Bull; 2024; 47(5):967-977. PubMed ID: 38763751
[TBL] [Abstract][Full Text] [Related]
35. Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation.
Barnett S; Ogungbenro K; Ménochet K; Shen H; Lai Y; Humphreys WG; Galetin A
Clin Pharmacol Ther; 2018 Sep; 104(3):564-574. PubMed ID: 29243231
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial.
Yotsuyanagi H; Ohmagari N; Doi Y; Yamato M; Bac NH; Cha BK; Imamura T; Sonoyama T; Ichihashi G; Sanaki T; Tsuge Y; Uehara T; Mukae H
JAMA Netw Open; 2024 Feb; 7(2):e2354991. PubMed ID: 38335000
[TBL] [Abstract][Full Text] [Related]
37. P-Glycoprotein and Organic Anion Transporter Polypeptide 1B/Breast Cancer Resistance Protein Drug Transporter Activity in Pregnant Women Living With HIV.
Moreira FL; Melli PPDS; Marques MP; Rocha A; Nardotto GHB; Duarte G; Lanchote VL
J Clin Pharmacol; 2023 Feb; 63(2):219-227. PubMed ID: 36087110
[TBL] [Abstract][Full Text] [Related]
38. Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration.
Piscitelli J; Reddy MB; Wollenberg L; Del Frari L; Gong J; Wood L; Zhang Y; Matschke K; Williams JH
Clin Pharmacokinet; 2024 Apr; 63(4):483-496. PubMed ID: 38424308
[TBL] [Abstract][Full Text] [Related]
39. Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study.
Kalluri HV; Kikuchi R; Coppola S; Schmidt J; Mohamed MF; Bow DAJ; Salem AH
Clin Transl Sci; 2021 Jan; 14(1):373-381. PubMed ID: 33048456
[TBL] [Abstract][Full Text] [Related]
40. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.
Prueksaritanont T; Chu X; Evers R; Klopfer SO; Caro L; Kothare PA; Dempsey C; Rasmussen S; Houle R; Chan G; Cai X; Valesky R; Fraser IP; Stoch SA
Br J Clin Pharmacol; 2014 Sep; 78(3):587-98. PubMed ID: 24617605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
